Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

ABSTRACT: Partially unfolded alpha-lactalbumin forms the oleic acid complex HAMLET, with potent tumoricidal activity. Here we define a peptide-based molecular approach for targeting and killing tumor cells and evidence of its clinical potential (ClinicalTrials.gov NCT03560479). A 39-residue alpha-helical peptide from alpha-lactalbumin is shown to gain lethality for tumor cells by forming oleic acid complexes (alpha1-oleate). In a single center, placebo controlled, double blinded Phase I/II interventional clinical trial of non-muscle invasive bladder cancer, all primary end points of safety and efficacy of alpha1-oleate treatment are reached, as evaluated in an interim analysis. Intra-vesical instillations of alpha1-oleate triggers massive shedding of tumor cells and the tumor size is reduced but no drug-related side effects are detected (primary endpoints). Shed cells contain alpha1-oleate, treated tumors show evidence of apoptosis and the expression of cancer-related genes is inhibited (secondary endpoints). The results are especially encouraging for bladder cancer, where therapeutic failures and high recurrence rates create a great, unmet medical need.

ORGANISM(S): Homo sapiens

PROVIDER: GSE172112 | GEO | 2021/04/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate.

Project description:Potent chemotherapeutic agents are required to counteract the aggressive behavior of cancer cells and patients often experience severe side effects, due to tissue toxicity. This study addresses if a better balance between efficacy and toxicity can be attained using the tumoricidal complex alpha1-oleate, formed by a synthetic, alpha-helical peptide comprising the N-terminal 39 amino acids of alpha-lactalbumin and the fatty acid oleic acid. Bladder cancer was established, by intra-vesical instillation of MB49 cells on day 0 and the treatment group received five instillations of alpha1-oleate (1.7-17mM) on days 3-11. A dose-dependent reduction in tumor size, bladder size and bladder weight was recorded in the alpha1-oleate treated group, compared to sham-treated mice. Tumor markers Ki-67, Cyclin D1 and VEGF were inhibited in a dose-dependent manner, as was the expression of cancer-related genes. Remarkably, toxicity for healthy tissue was not detected in alpha1-oleate-treated, tumor bearing mice or in healthy mice or rabbits, challenged with increasing doses of the active complex. The results define a dose-dependent therapeutic effect of alpha1-oleate in a murine bladder cancer model.

2020-04-09 | GSE148308 | GEO

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate alone or in combination Epirubicin or Mitomycin C, long-term effects

Project description:Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of non-muscle invasive bladder cancer. This study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least four weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer.

2023-02-25 | GSE209881 | GEO

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate alone or in combination Epirubicin or Mitomycin C, short-term effects

2023-02-25 | GSE209882 | GEO

Expression data from Apcmin/+ mice treated with BAMLET

Project description:Tumor surveillance is essential to stop tumor progenitors in their tracks. Clearly, endogenous protective mechanisms other than immune surveillance are important, but their molecular nature and mechanisms of action remain unclear. In the newborn intestine, the immature cells need to be surveilled to promote differentiation and tumor development prevented. This study addressed if molecules in milk may be relevant for tumor surveillance. Alpha-lactalbumin, which is the most abundant protein in human milk and crucial for the survival of mammals, due to its role in lactose synthesis, also forms tumoricidal oleic-acid complexes with documented therapeutic efficacy. This study identifies BAMLET, a complex formed by bovine alpha-lactalbumin and oleic acid, as a tumor surveillance molecule. BAMLET substitution of the drinking water protected tumor-prone ApcMin/+ mice from developing intestinal cancer and prolonged their survival, with pronounced inhibition of genes regulating the tumor environment, metastasis, Wnt/β-catenin signaling and cancer related gene networks. Unexpected extra-intestinal effects on lungs, livers, kidneys and spleens further suggested a protective effect of BAMLET beyond the intestine. These effects were specific for the cancer-prone ApcMin/+ mice. Healthy C57BL/6 mice were largely unaffected by peroral BAMLET administration, except for improved metabolic functions such as lipid and glucose metabolism and insulin resistance and there was no evidence of toxicity. The results suggest that molecules, which have evolved to support tissue differentiation, may identify and remove tumor progenitors. The findings support the potential of BAMLET as a tumor surveillance molecule with potential for clinical use in cancer-prone patients.

2024-02-12 | GSE235766 | GEO

Expression data from healthy C57BL/6 mice treated with BAMLET

2024-02-12 | GSE235765 | GEO

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate.

Project description:Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate.

| PRJNA623875 | ENA

Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

Project description:Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

| PRJNA722034 | ENA

Free fatty acid and α‐lactalbumin‐oleic acid complexes in preterm human milk are cytotoxic to fetal intestinal cells in vitro

Project description:Human milk, the best enteral selection for a preterm infant, becomes altered during freezing and soluble free fatty acid is generated over time. Free fatty acids may form complexes, such as the oleic acid-bound protein called HAMLET (human α‐lactalbumin made lethal to tumor cells). We determined the in vitro biological activity of preterm human milk protein‐oleic complexes (HAMLET-like complexes) and tested the hypothesis that laboratory-synthesized HAMLET exhibits cytotoxicity in human immature epithelial intestinal cell culture. Thirty-four milk samples from 15 mothers of hospitalized preterm infants were donated over time. Milk fractions were tested repeatedly for FHs 74 Int and HIEC-6 fetal cell cytotoxicity, using a sensitive viability assay. Protein and fatty acid identities were confirmed by Western blot, high performance liquid chromatography, and mass spectrometry. Cytotoxicity of intestinal cells exposed to milk increased respective to milk storage time (p<0.001) and was associated with free oleic acid (p=0.009). Synthesized HAMLET was cytotoxic in cultures of both lines. Preterm milk samples killed most cells in culture after an average 54 days in frozen storage (95% C.I. 34-72 days). After prolonged storage time, preterm milk and HAMLET showed a degree of cytotoxicity to immature intestinal cells in culture. Protein was reduced 221 in 1 mM dithiothreitol and alkylated in 5.5 mM

2022-08-12 | PXD034652 | Pride

Sunflower seed proteome analysis by iTRAQ

Project description:Comparative proteomic analysis between high-oleate ('L-1-OL-1') and low-oleate ('86-1') maintainer lines of sunflower based on iTRAQ (isobaric tags for relative and absolute quantification) was performed to identify key oleic acid synthesis-related proteins. These findings should enhance understanding of sunflower seed oleic acid synthesis mechanisms toward improving oil quality through breeding and germplasm-based measures.

2022-07-01 | PXD035059 | iProX

Gene expression profiling in primary human skeletal myotubes with small molecule inhibitors of lipid accumulation

Project description:The development of insulin resistance is strongly associated with accumulation of intracellular lipid in tissues outside of adipose including skeletal muscle, liver and heart. In obese humans, intramyocellular lipid (IMCL) is negatively correlated with whole body insulin sensitivity. The skeletal myocyte imports fatty acids (FA) into the cell from circulating free fatty acids or lipoprotein particles such as VLDL, to support energy production. Once transported into the cell, FAs are oxidized for ATP production, used to build membranes, or stored as triglyceride. However, in the long term, increased delivery of fatty acids can exceed mitochondrial oxidative capacity and set the stage for a vicious cycle of cellular lipotoxicity. We have recently identified a novel small molecule inhibitor of lipid accumulation in skeletal mycytes termed SBI-477. Microarray transcriptomics was performed in primary human skeletal myotubes following oleate loading and treatment with SBI-477. This was also compared to A922500, a diacylglycerol transferase 1 (DGAT1) inhibitor. SBI-477 treatment reversed many of the transcriptomic effects of oleate loading in these cells but also produced a transcriptomic profile distinct from the DGAT1 inhibitor. Microarray expression profiling was performed with total RNA isolated from differentiated primary human skeletal myotubes. These cells were treated with BSA (control for oleate), 100micromolar oleic acid, oleate + 10micromolar SBI-477 and oleate + 1micromolar A922500 for 24 hours. Oleate and test compound were added at the same time to the cells. Two biologic replicates for each condition were included.

2016-08-08 | E-GEOD-77212 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data